Paras Healthcare Limited has completed a ₹1,450 crore initial public offering, with AZB & Partners advising the issuer and S&R Associates and Hogan Lovells Cadwalader acting for the book running lead managers. The offer comprised a ₹500 crore fresh issue and a ₹950 crore offer for sale by existing shareholders.
The IPO opened for public subscription from 21 to 23 October 2026, at a price band of ₹660-693 per equity share. The company’s reported listing date was October 28, the same date on which the Securities and Exchange Board of India (SEBI) portal recorded its final prospectus.
The transaction combined fresh capital for the healthcare provider, principally earmarked for debt repayment, with monetisation by its promoter and a private equity-linked shareholder. The distinction matters: ₹1,450 crore was the aggregate offer size, not the amount of fresh capital available to Paras Healthcare.
The completed offering also marked a reduction from the ₹1,800 crore transaction proposed in June. Anchor participation preceded a public book that closed at 2.23 times subscription, although demand varied materially across investor categories.
Key Highlights
Legal advisers: AZB & Partners advised Paras Healthcare; S&R Associates and Hogan Lovells Cadwalader acted as Indian and international counsel, respectively, to the lead managers.
Offer structure: The ₹1,450 crore IPO comprised a ₹500 crore fresh issue and a ₹950 crore offer for sale, reduced from the ₹1,800 crore proposal in June.
Selling shareholders: Promoter Dr Dharminder Kumar Nagar offered shares worth ₹300 crore, while Commelina, a Creador affiliate, offered shares worth ₹650 crore.
Use of proceeds: ₹375 crore of net fresh-issue proceeds was earmarked for debt repayment, against reported consolidated borrowings of ₹888.9 crore in June 2026.
Investor response: Anchors committed ₹652.5 crore. The public offer drew 2.23 times subscription, with the non-institutional portion remaining below full subscription.
Paras Healthcare's ₹1,450 crore IPO brings AZB, S&R and Hogan Lovells Cadwalader on board
The Paras Healthcare IPO brought together issuer-side counsel and separate Indian and international counsel for the intermediaries managing the offer. JM Financial Limited, BofA Securities India Limited and Nuvama Wealth Management Limited were the three book running lead managers, as identified in the National Stock Exchange’s issue record.
The issuer operates the Paras Hospitals business, described in the transaction material as a multi-speciality healthcare provider established in 2006. That business milestone is distinct from the company’s legal incorporation: the draft prospectus traces the corporate entity to December 21, 1987, when it was incorporated as Arbian Frozen Foods Private Limited.
The company changed its name to Paras Healthcare Private Limited in July 2003, reflecting its transition from frozen foods to healthcare services. Following board and shareholder resolutions in June 2024, a fresh incorporation certificate recording its conversion into a public company was issued on July 18, 2024. The draft also records a September 2025 adjustment removing the terminal full stop from its registered name.
AZB advises the issuer as S&R and Hogan Lovells Cadwalader represent the lead managers
AZB & Partners’ team was led by Senior Partner Agnik Bhattacharyya and Partner Sweta Ananthanarayanan, supported by Senior Associate Tanaiy Tewari. The firm’s earlier reported mandate on the proposed offering covered Paras Hospitals and promoter selling shareholder Dr Dharminder Kumar Nagar.
S&R Associates served as Indian legal counsel to the book running lead managers. Hogan Lovells Cadwalader acted as their international legal counsel. According to the transaction details supplied for the report, the latter team was led by Biswajit Chatterjee, Head of the India Practice and Dubai Office Managing Partner, with support from Counsel Varun Jetly and Associate Sanjana Ravjiani.
The separate mandates reflect the different responsibilities within a public offering. Issuer counsel typically assists with corporate authorisations, diligence and offer disclosures, while counsel to the lead managers advises on the intermediaries’ diligence and transaction documentation. International counsel brings an additional perspective to an offering involving overseas institutional participation. These are distinct advisory roles within the same capital-raising process, rather than representation in adversarial proceedings.
₹500 crore fresh issue and ₹950 crore OFS make up the final offer
The final offer retained a ₹500 crore fresh issue but reduced the offer-for-sale component to ₹950 crore. The June 2026 proposal had contemplated a ₹1,800 crore transaction comprising the same fresh-issue amount and a ₹1,300 crore OFS. The ₹350 crore reduction therefore came from the proposed shareholder sell-down, not the fresh capital component.
The offering had evolved over a longer period. The company’s annual report records an earlier draft red herring prospectus dated July 31, 2024, proposing a fresh issue of up to ₹400 crore and an OFS of up to 1,49,74,010 shares. Those terms belonged to an earlier proposal and should not be conflated with the completed October 2026 transaction.
The revised draft abridged prospectus was dated June 4, 2026, and SEBI’s filing page was dated June 18. Contemporary reporting placed regulatory clearance of the refiled papers in August, followed by filing of the red herring prospectus with the Registrar of Companies on October 14. The June draft’s cover expressly directed readers to the statutory framework:
“Please read Section 32 of the Companies Act, 2013”.
Section 32 concerns red herring prospectuses, which permit an offering to proceed before complete pricing or quantum particulars are settled. This staged documentation explains why an earlier draft’s proposed size cannot substitute for the final offer terms.
The ₹950 crore OFS consisted of shares worth ₹300 crore offered by Dr Dharminder Kumar Nagar and ₹650 crore offered by Commelina, a Creador affiliate. Together, these sales represented the larger component of the completed IPO.
An OFS transfers existing shares from selling shareholders to investors. Unlike a fresh issue, it does not generate fresh equity capital for the company. Consequently, the proceeds attributable to this component accrue to the selling shareholders, rather than becoming funds available to Paras Healthcare for debt repayment or business expenditure.
This distinction is central to reading the transaction. The IPO combined company fundraising with shareholder monetisation; it was not a ₹1,450 crore infusion into the hospital operator. Equally, participation in an OFS does not, without further shareholding information, establish that a seller has exited entirely. The reported sale values alone do not support conclusions about the sellers’ precise post-offer holdings or control position.
₹375 crore of fresh proceeds earmarked for debt repayment
Paras Healthcare intended to apply ₹375 crore of net fresh-issue proceeds towards debt repayment. Contemporary reporting placed consolidated borrowings at ₹888.9 crore as of June 2026, making deleveraging a central stated objective of the fundraising.
The earmarked repayment amount equalled three-fourths of the ₹500 crore gross fresh-issue size. That comparison indicates the prominence of debt reduction within the offer, but it is not a calculation of the company’s eventual post-IPO borrowings. Net proceeds depend on applicable issue expenses, while the ultimate debt position also depends on intervening borrowing, repayment and deployment.
Use-of-proceeds disclosures allow investors to distinguish funding for the company’s balance sheet from payments to selling shareholders. Here, the disclosed debt-repayment objective does not support describing the entire IPO as financing hospital expansion. Nor does an earmarked amount establish that repayment had already occurred by listing. The relevant next stage is actual utilisation of the fresh proceeds and the associated reporting obligations applicable to a listed issuer.
Anchor investors commit ₹652.5 crore ahead of the October subscription window
Anchor investors committed ₹652.5 crore on October 19, 2026, ahead of the public subscription window. Reported participants included Abu Dhabi Investment Authority, BlackRock Global Funds, Eastspring Investments, Government Pension Fund Global, Natixis International Funds, Integrated Core Strategies (Asia) and Citigroup Global.
The commitment was part of the IPO, not an additional ₹652.5 crore over and above the ₹1,450 crore offer. Anchor participation provides an early institutional allocation before public bidding opens, but it does not by itself establish how every subsequent investor category will respond or how the shares will trade after listing.
The NSE issue record also set out the payment mechanism for applications:
“All Investors shall mandatorily use only Application Supported by Blocked Amount (ASBA) facility for making payments.”
ASBA blocks application funds pending the allotment process, rather than treating every bid as an immediate completed investment. The exchange record identified ICICI Bank and HDFC Bank as sponsor banks and fixed October 23, 2026, at 5 p.m. as the UPI mandate-confirmation cut-off. These operational requirements formed part of the application process alongside the price band and subscription dates.
IPO draws uneven demand across QIB, retail and non-institutional categories
The offer closed with reported overall subscription of 2.23 times. Qualified institutional buyers, excluding anchors, subscribed 3.09 times their portion, while the retail category recorded subscription of 2 times. The non-institutional investor portion stood at 0.66 times.
The figures show that institutional and retail demand exceeded the shares available in their respective categories, while non-institutional demand fell short of full subscription. An undifferentiated description of strong demand would therefore obscure an important feature of the book. Overall subscription is an aggregate measure, not evidence that each category attracted equivalent interest.
The June draft abridged prospectus placed the offer under Regulation 6(2) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018. It stated that the company did not fulfil the Regulation 6(1)(a) condition concerning monetary assets as a proportion of net tangible assets. This was the eligibility basis disclosed in that draft; it should not be treated as a verbatim statement of every final allocation condition.
Institutional participation is significant within that regulatory framework, but subscription multiples remain demand indicators rather than investment guarantees. They do not establish the eventual listing premium, future liquidity or the company’s operating performance.
Paras Healthcare lists on October 28 after the final prospectus filing
The available IPO record identifies October 28, 2026 as Paras Healthcare’s listing date. SEBI’s portal records the final prospectus on the same date, under the classification:
“Public Issues : Final Offer Documents filed with ROC”.
The records thus place both the listing and final-prospectus entry on October 28; they do not establish their precise intraday sequence. They also do not establish an opening trading price or listing-day return. Neither an asserted premium nor a discount can be inferred from the subscription figures.
MUFG Intime India Private Limited was identified by the NSE as registrar to the issue. With the offering completed, the focus moves from bidding and allotment to continuing listed-company compliance and deployment of the fresh proceeds in accordance with the disclosed objects. The financial distinction remains unchanged: ₹500 crore represented fresh issuance, while ₹950 crore represented sales by existing shareholders.
Legal representation: AZB & Partners advised Paras Healthcare, with Agnik Bhattacharyya, Sweta Ananthanarayanan and Tanaiy Tewari on the team. S&R Associates acted as Indian counsel to JM Financial Limited, BofA Securities India Limited and Nuvama Wealth Management Limited. Hogan Lovells Cadwalader acted as international counsel to the lead managers, with Biswajit Chatterjee, Varun Jetly and Sanjana Ravjiani identified in the supplied transaction details.
Sources
